Show simple item record

dc.contributor.authorCotton, Thomas Richard
dc.date.accessioned2019-01-30T15:57:50Z
dc.date.available2019-01-30T15:57:50Z
dc.date.issued2019-06-29
dc.date.submitted2018-09-18
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/288560
dc.description.abstractMyostatin is a secreted growth factor of the transforming growth-factor $\beta$ (TGF$\beta$) superfamily, and a powerful negative regulator of muscle mass in vertebrates. As such, there is considerable interest in developing pharmacological agents which inhibit myostatin signalling in order to stimulate muscle growth in the context of pathological muscle wasting. Like other TGF$\beta$ family proteins, myostatin is biosynthesised as an inactive (latent) precursor protein which requires proteolytic processing to liberate the mature bioactive growth factor. To examine the molecular basis of pro-myostatin latency and the mechanism by which it is activated in the extracellular space, I have determined the crystal structure of unprocessed human pro-myostatin and studied the properties of the protein at various stages of activation. Crystallographic analysis of pro-myostatin reveals a unique domain-swapped dimeric structure, with an open V-shaped conformation distinct from the prototypical family member, TGF$\beta$1. Following cleavage of the prodomains by furin, pro-myostatin persists as a stable non-covalent complex which is resistant to the natural inhibitor follistatin and exhibits significantly weaker bioactivity than the mature growth factor. A number of distinct structural features combine to stabilise the interaction between pro and mature domains and in doing so confer latency to the pro-complex. This facilitates a controlled, step-wise process of activation in the extracellular space and contributes to a complex network of regulatory control. The results presented here provide a structural basis for understanding the effect of natural polymorphisms on myostatin function and a starting point for structure-guided development of next generation myostatin inhibitors. As a proof-of-concept, I present preliminary data on prodomain derived stapled peptides as inhibitors of myostatin signalling.
dc.description.sponsorshipFunded by Herchel Smith Studentship
dc.language.isoen
dc.rightsAll rights reserved
dc.rightsAll Rights Reserveden
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved/en
dc.subjectMyostatin
dc.subjectTGF-beta
dc.subjectMuscle
dc.subjectX-ray crystallography
dc.subjectprodomain
dc.subjectlatency
dc.subjectactivation
dc.subjectextracellular matrix
dc.subjectCrystal structure
dc.subjectpro-myostatin
dc.subjectgrowth factor
dc.subjectsignalling
dc.titleThe structure of human pro-myostatin and molecular basis of latency
dc.typeThesis
dc.type.qualificationlevelDoctoral
dc.type.qualificationnameDoctor of Philosophy (PhD)
dc.publisher.institutionUniversity of Cambridge
dc.publisher.departmentBiochemistry
dc.date.updated2019-01-28T20:11:13Z
dc.identifier.doi10.17863/CAM.35842
dc.contributor.orcidCotton, Thomas Richard [0000-0001-6709-9218]
dc.publisher.collegeChurchill
dc.type.qualificationtitlePhD Biochemistry
cam.supervisorHyvonen, Marko
cam.supervisor.orcidHyvonen, Marko [0000-0001-8683-4070]
cam.thesis.fundingfalse


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record